Wieloletnie doświadczenia z zastosowaniem ranibizumabu w leczeniu postaci wysiękowej AMD - przykłady kliniczne

• Authors: Halina Wykrota , Krzysztof Trzciąkowski

Title variants

EN

Long-term experience with treatment of AMD with use of ranibizumab – clinical examples

• Languages of publication: PL

Abstracts

PL

Podejmowane od wielu lat próby leczenia wysiękowej postaci AMD zaowocowały opracowaniem i wprowadzeniem do praktyki klinicznej leków blokujących aktywność VEGF. Spośród obecnie dostępnych leków stosowany od ośmiu lat ranibizumab ma najmocniej udowodnione w badaniach klinicznych skuteczność i bezpieczeństwo. We własnym materiale kilku tysięcy iniekcji zaobserwowaliśmy minimalną liczbę działań niepożądanych, w tym żadnych poważnych niepożądanych działań leku. Przedstawiamy przypadki kliniczne pacjentów z wysiękową postacią AMD leczonych skutecznie w długim okresie za pomocą iniekcji doszklistkowych ranibizumabu. Lek ten obecnie stosujemy z powodzeniem nie tylko w wysiękowym AMD, ale także w czterech innych wskazaniach: BRVO, CRVO, DME i mCNV.

EN

Years of trials of treating the wet form of AMD resulted in the development and introduction into clinical practice the VEGF-blocking drugs. Among the drugs currently available ranibizumab which is used for eight years now has the strongest evidence of its efficacy and safety, proved by large number of clinical studies. In our material of several thousand injections we have observed minimum number of adverse drug reactions and no serious adverse drug reactions. We are aiming to present the clinical examples of patients with neovascular AMD treated effectively with the injections of intravitreal ranibizumab in the long term of observation. Ranibizumab is currently used by us successfully not only in exudative AMD but also in four other treatment indications: BRVO, CRVO, DME and mCNV.

Keywords

EN

AMD; leczenie anty-VEGF; ranibizumab

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2014
• Volume: 1
• Issue: 2
• Pages: 76-83

Contributors

author

Halina Wykrota

• Ośrodek Mikrochirurgii Oka OPTOMED w Katowicach

author

Krzysztof Trzciąkowski

• Ośrodek Mikrochirurgii Oka OPTOMED w Katowicach

References

• 1. Macular Photocoagulation Study Group: Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch. Ophthalmol. 1997; 115(6): 741-747.
• 2. Macular Photocoagulation Study Group: Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch. Ophthalmol. 1994; 112(4): 480-488.
• 3. Bressler N.: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials – tap report 2. Arch. Ophtalmol. 2001; 119(2): 198-207.
• 4. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group: Verteporfin Therapy for Subfoveal Choroidal Neowascularization in Age-Related Macular degeneration. Arch. Ophthalmol. 2002; 120: 1307-1314.
• 5. Tatar O., Adam A., Shinoda K. et al.: Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am. J. Ophthalmol. 2006; 142(1): 95-104.
• 6. Ferrara N., Gerber H., Lecouter J.: The biology of VEGF and its receptors. Nat. Med. 2003; 99(6): 669-676.
• 7. Gragoudas E., Adamis A., Cunningham E. et al.: Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 2004; 351(27): 2805-2816.
• 8. Avery R., Pieramici D., Rabena M. et al.: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113 (3): 363-372.
• 9. Rosenfeld P., Brown D., Heier J. et al.: MARINA Study Group.: Ranibizumab for neovascular age- related macular degeneration. N. Engl. J. Med. 2006; 355: 1419-1431.
• 10. Larsen M., Schmidt-Erfurth U., Lanzetta P. et al.: Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results. Ophthalmology 2012; 119(5): 992-1000.
• 11. Holz G., Amoaku W., Donate J. et al.: Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology 2011; 118(4): 663-671.
• 12. Chakravarthy U., Harding S., Rogers C. et al.: IVAN study investigators: Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 9900(382): 1258-1267.
• 13. Kaiser P., Boyer D., Cruess A., Slakter J. et al.: DENALI Study Group: Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012; 119(5): 1001-1010.
• 14. Busbee B., Ho A., Brown D. et al.: HARBOR Study Group: Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013; 120(5): 1046-1056.
• 15. Mitchell P., Korobelnik J., Lanzetta P. et al.: Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br. J. Ophthalmol. 2010; 94(1): 2-13.
• 16. Ying G., Kim B., Maguire M. et al.: for the CATT Research Group: Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol. 2014 May 29 [online: doi: 10.1001/jamaophthalmol.2014.1019].
• 17. Fung A., Lalwani G., Rosenfeld P. et al.: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am. J. Ophthalmol. 2007; 143(4): 566-583.
• 18. Lalwani G., Rosenfeld P., Fung A. et al.: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am. J. Ophthalmol. 2009; 148(1): 43-58.
• 19. Jackson T., Dugel P., Bebchuk J. et al.: CABERNET Study Group: Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. Ophthalmology 2013; 120(8): 1597-1603.
• 20. Schmidt-Erfurth U., Kaiser P., Korobelnik J. et al.: Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014; 121(1): 193-201.
• 21. Holz F., Bandello F., Gillies M. et al.: on behalf of the LUMINOUS Steering Committee: Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme Br. J. Ophthalmol. 2013; 97(9): 1161-1167.
• 22. Lucentis (ranibizumab). Charakterystyka produktu leczniczego. 05.2014.

• Document Type: article